NDAINTRAVENOUSPOWDERPriority Review
Approved
Feb 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
4
Data completeness
5/8 — Partial
Priority Review
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COSELA (trilaciclib) is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor administered intravenously as a powder formulation. It is designed to preserve bone marrow function and reduce chemotherapy-induced myelosuppression in cancer patients. The drug protects hematopoietic stem and progenitor cells during chemotherapy treatment.
$0.080MPart D
Peak14.4 years to LOEEarly-stage product in peak commercial phase with minimal Medicare adoption (11 Part D claims in 2023), suggesting narrow current market penetration and significant growth runway for commercial teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer
Started Mar 2026
120 enrolled
Limited Stage Small Cell Lung Cancer
Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer
Started Jan 2024
36 enrolled
Metastatic Triple-Negative Breast Cancer
Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan
Started Oct 2023
302 enrolled
Extensive-stage Small-cell Lung Cancer
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC
Started Jun 2017
107 enrolled
Small Cell Lung Cancer
Worked on COSELA at Pharmacosmos? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.